BCMAS® Medical Affairs Decision Guide Study Guide

Apply it

An AI draft states that a trial reduced mortality by 30%, but its cited article reports hospitalization. Compare the draft with the actual study, remove the unsupported mortality claim, and correct the endpoint before review.

Apply it

A team considers an AI tool for extracting trial eligibility criteria. Test representative protocols against independently checked extractions, including complex exceptions, and assess omitted exclusions before deciding whether the tool can support that workflow.

Apply it

A scientific inquiry classifier performs well overall but frequently misroutes questions written in a less common language. Examine language-specific errors and sample sizes, improve the affected workflow, and reassess before expanding its use.

Apply it

After a literature-summary tool is updated, reviewers notice repeated omission of confidence intervals. Log the pattern, assess affected summaries, require correction of the missing uncertainty, and reevaluate performance before relying on the revised system.

Apply it

Clinicians cannot explain whether trial findings apply to patients with renal impairment. Define an objective to improve understanding of the available evidence and its limits, then assign an evidence review and targeted scientific discussion.

Apply it

A launch team has completed slide production but cannot explain a pivotal study's discontinuation analysis. Treat that interpretive gap as unfinished readiness, assign expert review, and update field training before using the study materials.

Apply it

A field training session requires a finalized analysis that clinical development expects two weeks later than planned. Identify the affected materials and reviewers, revise the training sequence, and communicate the resulting scientific support gap.

Apply it

A team must choose between another general disease webinar and investigating repeated confusion about a serious safety limitation. Assess consequences and available corrective evidence, then prioritize the activity most likely to improve the consequential decision.

Apply it

A randomized study has slightly more older participants in one group. Examine the randomization process and prespecified analysis rather than declaring the trial invalid solely because the baseline age distributions are not perfectly identical.

Apply it

Recruiters can see tomorrow's assignment list, although outcome assessors remain blinded. Identify compromised allocation concealment: recruiters could influence who enters each group before assignment, and assessor blinding cannot repair that enrollment bias.

Apply it

A small early study shows a favorable biomarker change at a tolerable dose. Describe it as supporting dose and development decisions; examine later comparative evidence before claiming that treatment improves patient-important outcomes broadly.

Apply it

A trial asks whether assignment improves symptoms regardless of rescue medication use. Continue collecting symptom outcomes after rescue treatment and interpret the effect as answering that treatment-policy question, rather than excluding rescue users automatically.

Apply it

The primary treatment-policy analysis assumes outcomes are missing at random. Reestimate that same treatment effect under plausible departures from this assumption, then assess whether the interpretation changes materially across the resulting sensitivity analyses.

Apply it

A team describes a digital product as simple software and assumes minimal regulation. First examine its intended clinical function and applicable FDA classification, then determine which controls apply to that specific device type.

Apply it

Two proposed class II devices appear similar, but one falls within a listed exemption and the other exceeds its limitations. Compare their intended uses and applicable requirements before assuming both require identical premarket submissions.

Apply it

A reference-standard study includes 100 affected and 200 unaffected participants. The test identifies 90 affected participants and correctly excludes 180 unaffected participants; sensitivity and specificity are each 90%, using their separate condition-based denominators.

Apply it

Among 1,000 people with 1% prevalence, a 90%-sensitive, 90%-specific test yields about nine true positives and 99 false positives. Its positive predictive value is approximately 8.3%, making the testing context essential to interpretation.

Apply it

A biomarker accurately identifies a disease subtype, but treatment is unchanged for either result. Explain the demonstrated classification performance while distinguishing it from an unproven claim that testing improves survival or quality of life.

Apply it

A company announces that a drug has entered phase 2. Explain that the product remains investigational for that program and that entry into patient research does not demonstrate FDA approval for routine marketing.

Apply it

A pivotal study meets its efficacy endpoint, but manufacturing consistency remains unresolved. Explain why the efficacy finding does not settle the application: FDA also evaluates quality controls and the overall benefit-risk and labeling package.

Apply it

Suppose a treatment receives accelerated approval based on tumor response in a serious cancer. Explain the observed response, the meaningful advantage supporting eligibility relative to available therapy, and the remaining uncertainty about patient benefit. Describe the confirmatory study's role in verifying clinical benefit. Do not claim improved survival unless survival evidence actually demonstrates it.

Apply it

A team argues that any biomarker improvement supports traditional approval because the marker is biologically plausible. Ask whether evidence validates prediction of clinical benefit in this context or supports only a reasonably likely relationship.

Apply it

A statistician contributes substantially to analysis and interpretation but has not reviewed the manuscript. Invite critical intellectual revision, final approval and accountability discussion before deciding whether the complete authorship criteria have been met.

Apply it

A professional writer improves language and formatting without contributing qualifying intellectual work or accepting author accountability. Describe the assistance and its support in acknowledgments, obtain appropriate permission, and avoid granting automatic authorship.

Apply it

A journal requests missing trial registration and disclosure information. The corresponding author coordinates complete responses with the author group and checks submission requirements, while each author remains responsible for their own disclosures and approval.

Apply it

In a hypothetical trial, the first participant consents for enrollment on June 2, registration materials are first submitted on June 4, and randomization occurs on June 10. Registration is late under ICMJE's policy despite preceding randomization. The publication team should document the consent and initial submission dates, explain the delay transparently, and compare registered outcomes with those reported.

Apply it

A manuscript emphasizes a favorable secondary endpoint while the registered primary endpoint was inconclusive. Retain clear reporting of the primary result and explain any outcome changes, including their timing and rationale, before interpreting the secondary finding.

Apply it

Treatment A costs $18,000 and yields 2.4 QALYs; treatment B costs $12,000 and yields 2.1 QALYs. The ICER for A versus B is $6,000 divided by 0.3, or $20,000 per QALY gained.

Apply it

One strategy provides two years at utility 0.8 followed by one year at 0.5. Its undiscounted total is 2 × 0.8 plus 1 × 0.5, or 2.1 QALYs, under those stated assumptions.

Apply it

A treatment reduces missed work but increases insurer spending. Present the productivity effect separately when discussing a payer analysis, and include it appropriately in a stated societal analysis rather than mixing perspectives without explanation.

Apply it

A payer covers 2,000 eligible patients and expects 25% uptake. If incremental annual net cost is $3,000 per treated patient, the simplified first-year impact is 500 × $3,000, or $1.5 million, before additional modeled changes.

Apply it

A model favors treatment only when a benefit persists for ten years, but follow-up lasts two years. Compare shorter persistence scenarios and identify the duration assumption as a major source of decision uncertainty.

Apply it

At one year, an event occurs in 12% of controls and 8% of treated participants. The absolute reduction is four percentage points, and NNT is 1 divided by 0.04, or 25 over one year.

Apply it

A risk-difference estimate is a two-percentage-point reduction, with an interval from a one-point increase to a five-point reduction. Explain that the study remains compatible with no effect and potentially meaningful benefit rather than proving equivalence.

Apply it

A treatment comparison has a small p value in younger patients and a larger p value in older patients. Examine the interaction estimate and its uncertainty before claiming that age changes the treatment effect.

Apply it

An observational study finds fewer hospitalizations among users of a new treatment but lacks baseline disease severity. Consider whether clinicians preferentially selected healthier patients, and explain why adjustment for age alone cannot resolve that concern.

Apply it

A claims database contains treatment dispensings and admissions. It becomes a source for real-world evidence when a defined study analyzes those data to address a clinical question with explicit exposure, outcome and confounding methods.

Apply it

A patient develops bronchospasm requiring urgent treatment to prevent respiratory failure but is not admitted. Consider the medically important event criterion rather than dismissing seriousness solely because hospitalization did not occur in this case.

Apply it

One patient has a severe headache managed at home without qualifying consequences; another has a modest symptom that prompts medically necessary admission. Assess intensity and seriousness separately rather than assigning both cases the same classification.

Apply it

A clinician reports a stroke after treatment initiation in a patient with substantial vascular risk. Preserve the report's safety value while assessing timing, clinical history and competing explanations; avoid calling the temporal association proof of causation.

Apply it

Product A has 200 reports and product B has 80, but their use and reporting patterns differ. Explain that these counts cannot rank incidence without comparable exposure denominators, observation periods and reliable event ascertainment.

Apply it

A medicine's REMS requires specified prescriber and patient actions before dispensing. Explain those product-specific safe-use measures and their targeted serious risk rather than assuming ordinary distribution or general counseling fulfills the REMS.

Apply it

An investigator asks how rescue medication affected a trial's interpretation. Focus the discussion on the estimand, outcome collection and analysis rather than delivering a general product overview that leaves the methodological question unresolved.

Apply it

Three specialists independently misunderstand a trial exclusion criterion. Record their practice settings and the exact confusion, then propose reviewing existing educational materials while avoiding a claim that most specialists share the same misunderstanding.

Apply it

Field teams repeatedly hear concerns about monitoring burden, while inquiry data show questions concentrated in one practice setting. Examine that setting specifically before proposing a broad national educational initiative based on the field comments.

Apply it

A clinician asks whether a result applies to patients with a comorbidity excluded from the trial. Explain the exclusion, relevant available evidence and the resulting uncertainty, rather than presenting the pivotal estimate as directly established.

Apply it

A clinician asks whether a treatment is appropriate in renal disease. Clarify the renal impairment category and whether the question concerns labeling, study inclusion or safety findings before preparing the scientific response and its limitations.

Apply it

One randomized trial shows benefit while a small observational study does not. Summarize both relevant findings, compare their populations and methods, and explain why design and precision affect interpretation instead of choosing the preferred result.

Apply it

A global response describes an indication absent from the local label. The local team reviews the scientific content and applicable requirements, clearly distinguishes labeling status, and adapts the response before it is used locally.

Apply it

A new comparative trial changes the interpretation of an existing efficacy response. Review the findings, revise the global document, notify owners of linked local versions, and ensure outdated versions are no longer used.

Apply it

A potential participant signs quickly but believes the study guarantees the best treatment. Pause to clarify the research purpose, alternatives and uncertainty, assess understanding, and support a voluntary decision before treating consent as meaningful.

Apply it

A study recruits only economically disadvantaged patients because they are easy to access, although the research question concerns a broader population. Examine the selection rationale and whether burdens and potential benefits are being distributed fairly.

Apply it

An advisory board needs expertise in rare diagnostic workflows. Select participants with relevant experience, justify the number needed and define compensated work, rather than favoring clinicians because they generate the highest product sales.

Apply it

A record documents age 93 in 2026 and a birth year of 1933. Replace the exact age with '90 or older' and remove the birth year, because retaining 1933 would reveal an age above 89. Remove birth and admission months and days as well. An event year such as 2026 may generally remain, provided the retained information does not reveal the prohibited older-age detail and all other Safe Harbor requirements are satisfied.

Apply it

A commercial supporter offers funding only if its preferred speaker and efficacy slides are used. The accredited provider should retain independent faculty and content decisions rather than accept those conditions for the educational activity.

Apply it

An independent clinician who is neither an owner nor an employee reports paid consulting within the preceding 24 months. The consulting concerns a manufacturer's products discussed in the proposed session, making the relationship relevant. The provider documents appropriate mitigation, such as independent content review with required revisions, before the clinician assumes the faculty role. Learners receive the clinician's name, company name, relationship nature and a statement that relevant relationships were mitigated before engaging in the education.

Apply it

A team delivers 40 sessions intended to improve interpretation of confidence intervals. Report the sessions as activity, then assess learners' interpretation using suitable questions to examine whether the intended educational change actually occurred.

Apply it

An analyst can either refresh a routine dashboard or evaluate a consequential evidence gap this week. Consider the value of the best forgone analysis when choosing, even if both tasks require no additional cash payment.

Apply it

A workflow costs $20,000 and credibly saves $30,000 over the stated year. Net ROI is ($30,000 − $20,000) divided by $20,000, or 50%, assuming the savings are attributable and the relevant costs are complete.

Apply it

A team requests support for a study-applicability program. Specify the stakeholder knowledge gap, staffing and review needs, expected learning measure and dependence on an upcoming analysis, then explain how a delay would change delivery.